<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00077545</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02576</org_study_id>
    <secondary_id>NCI-2012-02576</secondary_id>
    <secondary_id>CDR0000352307</secondary_id>
    <secondary_id>UCCRC-12765A</secondary_id>
    <secondary_id>NCI-6285</secondary_id>
    <secondary_id>12765A</secondary_id>
    <secondary_id>6285</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00077545</nct_id>
  </id_info>
  <brief_title>3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction</brief_title>
  <official_title>A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Drugs used in chemotherapy, such as 3-AP and cisplatin, work in different ways to stop tumor&#xD;
      cells from dividing so they stop growing or die. 3-AP may help cisplatin kill more cancer&#xD;
      cells by making them more sensitive to the drug. This phase II trial is studying how well&#xD;
      giving 3-AP together with cisplatin works in treating patients with recurrent or metastatic&#xD;
      adenocarcinoma of the esophagus or gastroesophageal junction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate in patients with recurrent or metastatic&#xD;
      adenocarcinoma of the esophagus or gastroesophageal junction treated with 3-AP (Triapine) and&#xD;
      cisplatin.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the toxicity of this regimen in these patients. II. Determine the duration of&#xD;
      response and overall survival of patients treated with this regimen.&#xD;
&#xD;
      III. Determine the palliative benefits with regard to dysphagia in patients treated with this&#xD;
      regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin&#xD;
      IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for&#xD;
      up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-39 patients will be accrued for this study within 20 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be calculated together with 95% confidence intervals based on the binomial distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (CR + PR)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Will be calculated together with 95% confidence intervals based on the binomial distribution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Kaplan-Meier estimates will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the start of treatment to progression or death, assessed up to 2 years</time_frame>
    <description>Kaplan-Meier estimates will be determined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>From the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with various treatment-related toxicities assessed using NCI CTCAE version 3.0</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with improvement of dysphagia</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of improvement of dysphagia</measure>
    <time_frame>Up to 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Adenocarcinoma of the Esophagus</condition>
  <condition>Recurrent Esophageal Cancer</condition>
  <condition>Stage IV Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4. Patients also receive cisplatin IV over 60 minutes on days 2 and 3 before 3-AP infusion. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triapine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (triapine and cisplatin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed adenocarcinoma of the esophagus or&#xD;
             gastroesophageal junction&#xD;
&#xD;
               -  Metastatic or recurrent disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques&#xD;
                  OR ≥ 10 mm by spiral CT scan&#xD;
&#xD;
               -  Outside prior irradiation port&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 50-100%&#xD;
&#xD;
          -  More than 6 months&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500/mm^3&#xD;
&#xD;
          -  WBC ≥ 3,000/mm ^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  Creatine normal&#xD;
&#xD;
          -  Creatinine clearance ≥ 50 mL/min&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No uncontrolled congestive heart failure&#xD;
&#xD;
          -  No pulmonary disease requiring supplemental oxygen&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No glucose-6-phosphate dehydrogenase (G6PD) deficiency (for patients of African,&#xD;
             Asian, or Mediterranean origin)&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No active or ongoing infection&#xD;
&#xD;
          -  No active second malignancy&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to 3-AP or other study agents&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  At least 1 year since prior platinum-derivative agents&#xD;
&#xD;
          -  No prior chemotherapy for metastatic or recurrent esophageal cancer&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 2 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ann Mauer</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>February 10, 2004</study_first_submitted>
  <study_first_submitted_qc>February 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2004</study_first_posted>
  <last_update_submitted>October 7, 2013</last_update_submitted>
  <last_update_submitted_qc>October 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

